The upregulation of immune checkpoint ligand PD-L1 in tumour microenvironment

Scandinavian Journal of Immunology

Volumn 80, Issue 1, 2014, Pages 71-72

  Xu, W ^a   Jiang, H ^a   Gao, J ^a   Zhao, Y ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; STAT3 PROTEIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; HUMAN; IMMUNOGENICITY; LETTER; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; TUMOR CELL; TUMOR MICROENVIRONMENT; UPREGULATION;

ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; MYELOID CELLS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84902675853     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12177     Document Type: Letter

References (6)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
2. Parsa AT, Waldron JS, Panner A et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84-8.
3. Akbay EA, Koyama S, Carretero J et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-63.
4. Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.
5. Spranger S, Spaapen RM, Zha Y et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5:200ra116.
6. Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014;124:687-95.